Effects of troglitazone on hepatic and peripheral insulin resistance induced by growth hormone excess in rats. (Q51569056)

7 April 2018

title

Effects of troglitazone on hepatic and peripheral insulin resistance induced by growth hormone excess in rats. (English)

1 reference

7 April 2018

1 reference

Sugimoto M

1

1 reference

7 April 2018

Takeda N

2

1 reference

7 April 2018

Nakashima K

3

1 reference

7 April 2018

Okumura S

4

1 reference

7 April 2018

Takami K

5

1 reference

7 April 2018

Yoshino K

6

1 reference

7 April 2018

Hattori J

7

1 reference

7 April 2018

Ishimori M

8

1 reference

7 April 2018

Takami R

9

1 reference

7 April 2018

Sasaki A

10

1 reference

7 April 2018

Yasuda K

11

1 reference

7 April 2018

publication date

1 July 1998

1 reference

7 April 2018

number of pages

5

1 reference

based on heuristic

inferred from page(s)

published in

Metabolism

1 reference

7 April 2018

volume

47

1 reference

7 April 2018

issue

7

1 reference

7 April 2018

page(s)

783-787

1 reference

7 April 2018

Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

The effect of growth hormone on glucose metabolism and insulin secretion in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

In Vivo Hepatic and Peripheral Insulin Resistance in Genetically Obese (fa/fa) Rats*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Effect of biosynthetic human growth hormone on insulin action in individual tissues of the rat in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Growth hormone-induced insulin resistance and its relationship to lipid availability in the rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Influence of growth hormone on glucose-induced glucose uptake in normal men as assessed by the hyperglycemic clamp technique

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Short-term effects of growth hormone on fuel oxidation and regional substrate metabolism in normal man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Effect of growth hormone on carbohydrate and lipid metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Mechanism of signaling by growth hormone receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

The inhibition of insulin action and glucose metabolism by porcine growth hormone in porcine adipocytes is not the result of any decrease in insulin binding or insulin receptor kinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Insulin resistance in rats harboring growth hormone-secreting tumors: decreased receptor number but increased kinase activity in liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Skeletal muscle glucose transporter gene expression is not affected by injecting growth-hormone-secreting cells in young rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Pioglitazone Increases Insulin Sensitivity by Activating Insulin Receptor Kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

The oxazolidinedione CP-92,768-2 partially protects insulin receptor substrate-1 from dexamethasone down-regulation in 3T3-L1 adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Pioglitazone promotes insulin-induced activation of phosphoinositide 3-kinase in 3T3-L1 adipocytes by inhibiting a negative control mechanism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Regulation of glucose transport by pioglitazone in cultured muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2898%2990112-3

10.1016/S0026-0495(98)90112-3

7 January 2021

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

9667221

1 reference

7 April 2018